Pages
Products

Nipah Virus Research Solutions

Neutralization AssayRecombinant ProteinsmRNA-LNPsVLPsOverexpression Cell LinesAntibodiesMolecular Detection Kits

Overview

In January 2026, a new outbreak of Nipah virus (NiV) was reported in West Bengal, India, drawing significant international attention. The WHO subsequently reissued a public health alert, highlighting the virus's exceptionally high case fatality rate of 40%–75% and its potential pandemic risk. Compared with the Ebola virus, NiV is characterized by a more insidious onset, a longer and variable incubation period, and a zoonotic transmission cycle, making early detection and containment considerably more challenging. Although initial symptoms are often nonspecific, the disease can rapidly progress to severe encephalitis or acute respiratory failure within a short timeframe.

With no approved therapeutics or vaccines, NiV remains a high-risk pathogen in virology and immunology research. Leveraging expertise in recombinant proteins, nucleic acid delivery, virus-like particles (VLPs), and antibody engineering, Creative Biogene has developed a systematic and modular portfolio of Nipah virus research products to support multi-level scientific investigation, from fundamental mechanisms to translational applications.

Virological Characteristics and Genome Organization of Nipah Virus

Nipah virus belongs to the family Paramyxoviridae, genus Henipavirus, and is an enveloped, single-stranded negative-sense RNA virus. Viral particles exhibit pronounced pleomorphism, with diameters ranging from approximately 40 to 600 nm. The NiV genome is approximately 18.2 kb in length, substantially larger than that of most classical paramyxoviruses, a feature that underlies its complex transcriptional regulation and pathogenic potential.

The NiV genome encodes the following proteins in a 3′ to 5′ orientation:

  • N (nucleocapsid protein)
  • P (phosphoprotein)
  • M (matrix protein)
  • F (fusion protein)
  • G (glycoprotein)
  • L (RNA-dependent RNA polymerase)

Figure 1. Structure of Nipah virus.Figure 1. Structure of Nipah virus. (Singh RK, et al., 2019)

The N, P, and L proteins form the viral replication and transcription complex and are essential for maintenance of the viral life cycle. Through RNA editing, the P gene also gives rise to multiple non-structural protein variants, including the V, W, and C proteins. These proteins effectively antagonize host STAT1/STAT2 signaling pathways and constitute a key molecular basis for NiV-mediated suppression of innate immune responses and immune evasion.

Viral Entry and Transmission Mechanisms

Nipah Virus Pseudovirus Neutralization Assay Service

Creative Biogene provides a standardized pseudovirus-based neutralization assay for functional evaluation of NiV entry inhibition. NiV G/F–pseudotyped viral particles carrying a reporter gene are pre-incubated with test samples (sera, plasma, monoclonal antibodies, or antibody fragments) and then applied to permissive target cells expressing ephrin-B2/B3. The reduction of reporter signal relative to virus-only controls determines neutralizing activity.

NiV G and F glycoproteins are co-expressed with a replication-defective, reporter-encoding viral backbone to generate pseudoviruses.

Neutralization Step

The mixture is added to ephrin-B2/B3–expressing target cells, and reporter signal is quantified to assess viral entry.

Data Analysis

Pseudovirus Production

Serially diluted antibodies or serum samples are pre-incubated with pseudovirus.

Cell Infection & Readout

Neutralization curves are generated, and inhibitory titers are calculated.

Service Highlights

Quantitative neutralization readout

ID₅₀ / IC₅₀ values derived from dose–response curves.

BSL-2 compatible platform

no use of live Nipah virus.

Broad sample compatibility

serum, plasma, monoclonal antibodies, and antibody fragments.

Creative Biogene's Nipah Virus Research Product Portfolio

Focusing on key molecular targets and experimental checkpoints throughout the NiV infection cycle, Creative Biogene has established a comprehensive product matrix encompassing recombinant antigens, mRNA-LNP formulations, virus-like particles, stable overexpression cell lines, functional antibodies, and molecular detection tools. This integrated portfolio provides standardized reagents that can be readily aligned with experimental designs at different stages of NiV research.

Recombinant Proteins

Creative Biogene offers multiple formats of NiV recombinant proteins, including full-length G protein and functional domains, F protein in distinct conformational states (pre-fusion and post-fusion), as well as the human ephrin-B2 receptor protein. These products enable receptor-binding analyses, immunogenicity assessments, and antibody screening under non-infectious conditions, providing reliable and reproducible materials for both fundamental and immunological studies of NiV.

Cat. No.Product NameTargetTag / FormatSequence RegionPrice
NPP-001Nipah Virus Glycoprotein G, His TagGlycoprotein GHis Tag71–602Inquiry
NPP-002Nipah Virus Glycoprotein G (Head Domain), His TagGlycoprotein GHis Tag178–602Inquiry
NPP-003Nipah Virus Pre-Fusion Fusion Glycoprotein, His TagFusion GlycoproteinHis Tag27–487Inquiry
NPP-004Nipah Virus Post-Fusion Fusion Glycoprotein, His TagFusion GlycoproteinHis Tag27–99 & 117–488Inquiry
NPP-005Human Ephrin-B2 Protein, His TagEphrin-B2His Tag1–229Inquiry

mRNA-LNP Products

These products provide standardized antigen delivery tools for nucleic acid vaccine-related research, facilitating exploratory studies under non-infectious conditions.

Cat. No.Product NameTargetSequence RegionPrice
NPR-001Nipah Virus Glycoprotein G mRNA-LNPGlycoprotein G1–602Inquiry
NPR-002Nipah Virus Fusion Glycoprotein mRNA-LNPFusion Glycoprotein1–546Inquiry

Virus-Like Particles (VLPs)

Virus-like particles retain the native spatial organization of viral surface antigens while lacking viral genomic material, thereby combining enhanced biosafety with high structural and biological relevance.

Cat. No.Product NameTargetSequence RegionPrice
NPV-001Nipah Virus Glycoprotein G Full-Length Protein (VLP)Glycoprotein G1–602Inquiry
NPV-002Nipah Virus Fusion Glycoprotein Full-Length Protein (VLP)Fusion Glycoprotein1–546Inquiry

Overexpression Cell Lines

Creative Biogene provides stable HEK293 cell lines overexpressing NiV G or F proteins, suitable for studies of viral entry and membrane fusion mechanisms, antibody or receptor-blocking assays, and cell-based functional validation and imaging analyses.

Cat. No.Product NameTargetSequence RegionPrice
NPOE-001HEK293 Cell Line Overexpressing Nipah Virus Glycoprotein GGlycoprotein G1–602Inquiry
NPOE-002HEK293 Cell Line Overexpressing Nipah Virus Fusion GlycoproteinFusion Glycoprotein1–546Inquiry

Antibodies

Creative Biogene offers a panel of research-grade antibodies targeting NiV G and F proteins, available in IgG, Fab, and scFv formats. These antibodies support epitope mapping, neutralization, and blocking assays, and the development and optimization of ELISA, immunofluorescence, and related analytical methods.

Cat. No.Product NameTargetTag / FormatPrice
NPA-001Anti-Nipah Virus Glycoprotein G (HENV-26)Glycoprotein GMouse IgG1Inquiry
NPA-002Anti-Nipah Virus Glycoprotein G (HENV-32)Glycoprotein GMouse IgG1Inquiry
NPA-003Anti-Nipah Virus Glycoprotein G (nAH1.3)Glycoprotein GFabInquiry
NPA-004Anti-Nipah Virus Glycoprotein G (m102.3)Glycoprotein GFabInquiry
NPA-005Anti-Nipah Virus Glycoprotein G (m102.4)Glycoprotein GFabInquiry
NPA-006Anti-Nipah Virus Fusion Glycoprotein (5B3)Fusion GlycoproteinscFvInquiry
NPA-007Anti-Nipah Virus Fusion Glycoprotein (Fab66)Fusion GlycoproteinFabInquiry
NPA-008Anti-Nipah Virus Fusion Glycoprotein (1F5)Fusion GlycoproteinFabInquiry
NPA-009Anti-Nipah Virus Fusion Glycoprotein (12B2)Fusion GlycoproteinFabInquiry
NPA-010Anti-Nipah Virus Fusion Glycoprotein (14F8)Fusion GlycoproteinFabInquiry

Molecular Detection Kits

These kits can be applied in in vitro model validation, methodological development, and molecular-level analyses. When used in combination with recombinant antigens and antibodies, they support the construction of multi-layered and cross-validated NiV research workflows.

Cat. No.Product NamePrice
NPD-001Nipah Virus PCR Detection KitInquiry
NPD-002Nipah Virus qPCR Detection KitInquiry

Value to Researchers

Creative Biogene's Nipah virus research products are not a simple collection of isolated reagents, but rather a combinable and scalable toolkit designed around the mechanisms of NiV infection and pathogenesis. This portfolio supports:

  • Dissection of viral entry and host–virus interaction mechanisms
  • Vaccine antigen design and comparative immunogenicity studies
  • Neutralizing antibody screening and functional validation
  • Early-stage exploration of novel antiviral strategies

As research on highly pathogenic viruses increasingly emphasizes biosafety, standardization, and reproducibility, Creative Biogene is committed to providing reliable, transparent, and literature-aligned solutions for Nipah virus research, facilitating the steady translation of fundamental discoveries toward applied outcomes.

References:

  1. Singh RK, Dhama K, Chakraborty S, et al. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review. Vet Q. 2019 Dec;39(1):26-55.
  2. Al-Obaidi MMJ, Muthanna A, Desa MNM. Nipah Virus Neurotropism: Insights into Blood-Brain Barrier Disruption. J Integr Neurosci. 2024 Apr 29;23(5):90.
  3. Mohabbat A, Bannazadeh Baghi H. Chronic Neuroplasticity Changes Following Neurotropic Viral Infection: Mechanisms and Implications. Cell Mol Neurobiol. 2025 Nov 4;45(1):94.
* For research use only. Not intended for any clinical use.
Quick Inquiry